Subscribe to Search results

A paper provided to ACVSB members explained it was too early to report on the UKBTS study into surrogate testing and conclusions would not be drawn until the result of the Chiron tests were known.

Published on:

It was agreed at the meeting of the Advisory Committee on the Virological Safety of Blood that the use of Chiron or surrogate testing for HCV would be influenced by Chiron data once released.

Published on:

Dr Gunson recommended that the routine introduction of non-specific tests for HCV should be deferred unless necessary to acquire product licences.

Published on:

The Advisory Committee on Transfusion Transmitted Diseases agreed that Dr Gunson's report, both Chiron's test (now called the anti-HCV test) and NANBH surrogate screening, should be used as the basis for a paper to be submitted to the ACVSB.

Published on:

Dr Gunson presented a summary of results of the study on Alanine Amino-Transferase and Hepatitis B Core Screening of Blood Donations for an ACVSB meeting.

Published on:

The ACVSB felt that there was no case for using surrogate tests for Non-A Non-B Hepatitis.

Published on:

A report for a multi-centre study on Non-A Non-B Hepatitis surrogate screening was completed.

Published on:

Dr Kernoff wrote to Dr Colvin describing Non-A Non-B Hepatitis as "a serious disease with long-term consequences".

Published on:

Alter et al published a paper titled 'The Chronic Sequelae of Non-A Non-B Hepatitis B' in the Annals of Internal Medicine journal.

Published on:

A study by Ware et al titled 'Etiology of liver disease in renal transplant patients' reported that infection with NANBH accounted for much of serious, often fatal, complications of renal transplantation.

Published on:

In his written statement, Professor John Gillon noted that there was no doubt that screening with one or both of the the ALT or anti-HBc screening tests would have prevented some cases of NANBH, and in spite of the lack of data on the incidence of PTNANBH this would have been a desirable outcome.

Published on:

In a written submission to the Inquiry, SNBTS stated that they have on balance reached the conclusion that surrogate testing for NANBH should have been introduced.

Published on:

Alter et al wrote in the New England Journal of Medicine that 'surrogate assays for anti-HBc and alanine aminotransferase would have detected approximately half the anti-HCV-positive donors involved in the transmission of hepatitis they had identified.

Published on:

A study from Canada, published in the Lancet, found that 70 percent of hepatitis C infections would have been avoided by the use of the two surrogate markers, ALT and anti HBc.

Published on:

Journal article titled 'The Chronic Sequelae of Non-A Non-B Hepatitis B' described chronic NANBH as symptomatically mild and unaccompanied by physical signs or laboratory evidence of autoimmune disease or severe chronic liver disease..

Published on:

A report on NANB Hepatitis was prepared for the ACVSB. It described the issue of surrogate testing for NANBH as being "of some urgency" and suggested that it be a major item for the next meeting.

Published on:

Alter et al published a paper titled 'The Chronic Sequelae of Non-A Non-B Hepatitis B' in the Annals of Internal Medicine journal.

Published on:

The maximum pool size at BPL increased to 5,000 donations.

Published on:

Capacity to accommodate larger pool sizes increased at PFC.

Published on:

Maximum pool sizes at BPL increased to 7,500 donations.

Published on: